OZEMPIC® 0.5 mg is a once-weekly injectable semaglutide medication used to improve glycaemic control in adults with type 2 diabetes, alongside diet and exercise. The 0.5 mg strength is the first therapeutic dose following the initial 0.25 mg starter phase and is commonly used for continued glucose management and ongoing appetite regulation.

Key Benefits
• Therapeutic dosing for effective blood sugar reduction
• Helps support sustained weight loss by reducing appetite and calorie intake
• Once-weekly injection, offering convenient long-term management
• Can be used alone or combined with other diabetes treatments
• Proven to help reduce the risk of major cardiovascular events in eligible patients (as assessed by a clinician)

How It Works
OZEMPIC® contains semaglutide, a GLP-1 receptor agonist that enhances the body’s natural insulin response when blood sugar rises. It also slows gastric emptying, reduces glucagon secretion, and decreases hunger signals. These effects work together to improve glucose control and support weight reduction.

Ideal Candidates
• Adults with type 2 diabetes requiring improved glycaemic control
• Patients completing the 0.25 mg introductory phase
• Individuals seeking additional metabolic support, including weight reduction
• People who benefit from a once-weekly, easy-to-administer injection

Administration
Administered via a prefilled injection pen, injected subcutaneously once weekly into the abdomen, thigh, or upper arm.
The 0.5 mg dose is typically used for several weeks or longer, depending on patient response, before considering escalation to 1 mg or 2 mg as directed by a healthcare professional.

Possible Side Effects
Common side effects include nausea, vomiting, diarrhoea, constipation, abdominal discomfort, or reduced appetite. These may lessen over time as the body adjusts.
More serious but rare adverse events may include pancreatitis, gallbladder disorders, or severe gastrointestinal symptoms. All patients should be monitored by a qualified healthcare provider.